XY25026 is an orally active LRH-1 inhibitor with an IC50 of 0.28 µM. XY25026 inhibits the proliferation of androgen receptor (AR)-positive prostate cancer cells, suppresses the expression of AR target genes KLK2 and KLK3, and inhibits tumor growth in xenograft models. XY25026 is applicable to the research of castration-resistant prostate cancer[1].
Molekulargewicht:
470.60
Formel:
C30H34N2O3
Target-Kategorie:
Androgen Receptor,c-Myc,Orphan Nuclear Receptor
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
